Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
Aptose Biosciences (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company, announced that its common shares will be delisted from the Nasdaq Stock Market effective April 2, 2025. The delisting follows the company's failure to comply with Nasdaq's Listing Rule 5550(b)(1) equity requirement by the March 31, 2025 deadline, as mandated by the Nasdaq Hearings Panel's December 17, 2024 decision.
The company, which develops tuspetinib-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will continue trading on the Toronto Stock Exchange (TSX) under the symbol 'APS'. Aptose's management and board will review available options, including appealing the determination, while maintaining focus on executing their business plan and seeking future listing on a U.S. national Securities Exchange.
Aptose Biosciences (NASDAQ: APTO, TSX: APS), un'azienda di oncologia di precisione in fase clinica, ha annunciato che le sue azioni ordinarie saranno ritirate dal Nasdaq Stock Market a partire dal 2 aprile 2025. Il ritiro segue il mancato rispetto da parte dell'azienda del requisito di equity del Nasdaq's Listing Rule 5550(b)(1) entro la scadenza del 31 marzo 2025, come stabilito dalla decisione del Nasdaq Hearings Panel del 17 dicembre 2024.
L'azienda, che sviluppa una terapia di prima linea a base di tuspetinib per la leucemia mieloide acuta (AML) recentemente diagnosticata, continuerà a essere quotata sul Toronto Stock Exchange (TSX) con il simbolo 'APS'. La direzione e il consiglio di amministrazione di Aptose esamineranno le opzioni disponibili, inclusa la possibilità di fare appello alla decisione, mantenendo al contempo l'attenzione sull'esecuzione del loro piano aziendale e sulla ricerca di una futura quotazione su una borsa valori nazionale degli Stati Uniti.
Aptose Biosciences (NASDAQ: APTO, TSX: APS), una empresa de oncología de precisión en etapa clínica, anunció que sus acciones comunes serán eliminadas del Nasdaq Stock Market a partir del 2 de abril de 2025. La eliminación se produce tras el incumplimiento de la empresa con el requisito de capital del Nasdaq's Listing Rule 5550(b)(1) antes de la fecha límite del 31 de marzo de 2025, según lo dictado por la decisión del Nasdaq Hearings Panel del 17 de diciembre de 2024.
La empresa, que desarrolla una terapia de primera línea basada en tuspetinib para la leucemia mieloide aguda (AML) recién diagnosticada, continuará cotizando en el Toronto Stock Exchange (TSX) bajo el símbolo 'APS'. La dirección y la junta de Aptose revisarán las opciones disponibles, incluida la posibilidad de apelar la decisión, mientras mantienen el enfoque en ejecutar su plan de negocios y buscar una futura cotización en una bolsa de valores nacional de EE. UU.
Aptose Biosciences (NASDAQ: APTO, TSX: APS), 임상 단계의 정밀 종양학 회사가 2025년 4월 2일부터 나스닥 증권 거래소에서 상장 폐지될 것이라고 발표했습니다. 상장 폐지는 회사가 2025년 3월 31일 마감일까지 나스닥 상장 규칙 5550(b)(1)의 자본 요건을 준수하지 못한 데 따른 것입니다. 이는 나스닥 청문 위원회의 2024년 12월 17일 결정에 의해 의무화되었습니다.
이 회사는 새로 진단된 급성 골수성 백혈병(AML)을 위한 tuspetinib 기반의 1차 치료법을 개발하고 있으며, 토론토 증권 거래소(TSX)에서 'APS' 기호로 계속 거래될 것입니다. Aptose의 경영진과 이사회는 결정에 대한 항소를 포함한 가능한 옵션을 검토할 것이며, 사업 계획을 실행하고 미국의 국가 증권 거래소에서의 향후 상장을 추구하는 데 집중할 것입니다.
Aptose Biosciences (NASDAQ: APTO, TSX: APS), une entreprise de cancérologie de précision en phase clinique, a annoncé que ses actions ordinaires seront radiées du Nasdaq Stock Market à compter du 2 avril 2025. La radiation fait suite à l'incapacité de l'entreprise à respecter l'exigence de capital de la règle de cotation 5550(b)(1) de Nasdaq avant la date limite du 31 mars 2025, comme l'a stipulé la décision du Nasdaq Hearings Panel du 17 décembre 2024.
L'entreprise, qui développe une thérapie de première ligne à base de tuspetinib pour la leucémie myéloïde aiguë (LMA) nouvellement diagnostiquée, continuera à être cotée sur le Toronto Stock Exchange (TSX) sous le symbole 'APS'. La direction et le conseil d'administration d'Aptose examineront les options disponibles, y compris la possibilité de faire appel de la décision, tout en restant concentrés sur l'exécution de leur plan d'affaires et en recherchant une future cotation sur une bourse nationale américaine.
Aptose Biosciences (NASDAQ: APTO, TSX: APS), ein Unternehmen für präzise Onkologie in der klinischen Phase, gab bekannt, dass seine Stammaktien ab dem 2. April 2025 von der Nasdaq-Börse gestrichen werden. Die Streichung erfolgt, nachdem das Unternehmen die Eigenkapitalanforderungen der Nasdaq's Listing Rule 5550(b)(1) bis zur Frist am 31. März 2025 nicht erfüllt hat, wie in der Entscheidung des Nasdaq Hearings Panel vom 17. Dezember 2024 festgelegt.
Das Unternehmen, das eine frontline Therapie auf Basis von Tuspetinib für neu diagnostizierte akute myeloische Leukämie (AML) entwickelt, wird weiterhin an der Toronto Stock Exchange (TSX) unter dem Symbol 'APS' gehandelt. Das Management und der Vorstand von Aptose werden die verfügbaren Optionen prüfen, einschließlich der Möglichkeit, gegen die Entscheidung Berufung einzulegen, während sie sich darauf konzentrieren, ihren Geschäftsplan umzusetzen und eine zukünftige Notierung an einer US-amerikanischen Wertpapierbörse anzustreben.
- Continued listing on Toronto Stock Exchange (TSX) maintains market presence in Canada
- Company continues development of tuspetinib-based therapy for AML treatment
- Delisting from Nasdaq reduces U.S. market visibility and access to American investors
- Failure to meet Nasdaq's minimum equity requirements indicates financial challenges
- Loss of major exchange listing may impact stock liquidity and trading volume
SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the common shares of the Company from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”). Under the terms of the Panel’s December 17, 2024, decision in this matter (the “Decision”), the Company was required to demonstrate compliance with the Exchange’s equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”) on or before March 31, 2025. As indicated in the Decision, March 31st represented the full extent of the Panel’s discretion to grant continued listing while the Company was non-compliant with the Equity Rule. On March 31, 2025, through its advisor, the Company confirmed that it had been unable to regain compliance with the Equity Rule by that date. Accordingly, the Panel has determined to delist the Company’s common shares from Nasdaq and will suspend trading in those securities effective at the open of business on April 2, 2025.
The Company and board will review all available options, including an appeal to the determination, but will continue to execute its business plan and will seek to list on a U.S. national Securities Exchange at the appropriate time. Aptose’s shares remain listed on TSX under the symbol “APS”.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the Company’s delisting from NASDAQ and potential review of such decision and statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could includerisks detailed from time-to-time in our ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward- looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
For further information, please contact:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
FAQ
When will Aptose (APTO) be delisted from Nasdaq?
Why is Aptose (APTO) being delisted from Nasdaq?
Can investors still trade Aptose shares after the Nasdaq delisting?
What options is Aptose considering after the Nasdaq delisting notice?
